What's Happening?
A new documentary by journalist Hamilton Morris, titled 'The Chemistry of 7-OH,' provides an inside look at the production of 7-hydroxymitragynine at CBD American Shaman's facility in Kansas City. The film, which has garnered significant attention online,
arrives as federal regulators consider imposing restrictions on the compound. The U.S. Department of Health and Human Services is currently accepting public comments on the proposed threshold for 7-OH, with a deadline set for July 31. The documentary showcases the industrial synthesis process, including oxidation, HPLC analysis, and purification, while also addressing the controversy surrounding the compound's potential classification as a Schedule I substance by the DEA. CBD American Shaman's founder, Vince Sanders, emphasizes transparency and compliance with regulations, stating the company is prepared to meet any regulatory standards set.
Why It's Important?
The documentary and the ongoing regulatory discussions highlight the complex landscape surrounding kratom-derived compounds like 7-OH. The potential classification of 7-OH as a Schedule I substance could have significant implications for the hemp and botanical product industry, affecting manufacturers, consumers, and regulatory bodies. The debate centers on the safety and scientific data supporting the proposed threshold, with over 8,900 public comments already submitted. The outcome of this regulatory process could set a precedent for how similar compounds are treated in the future, impacting industry practices and consumer access to these products.
What's Next?
The public comment period for the proposed 7-OH threshold closes on July 31, after which the DEA will review the feedback before making a final decision. If the compound is classified as Schedule I, it could lead to stricter controls and limitations on its production and sale. Stakeholders, including industry groups and policy organizations, are likely to continue advocating for their positions, potentially influencing the final outcome. The documentary's release may also prompt further public and media interest in the regulatory process and the broader implications for the industry.
